ReviewESMO gastrointestinal oncology2025
Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer-is it justified?
Review in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal liver metastases (CRLM) pose a significant challenge in oncological care, with surgical resection offering the best chance for long-term survival. Despite curative-intent liver metastasectomy, recurrence rates remain high, underscoring the need for effective adjuvant therapies. While adjuvant chemotherapy (AC) improves disease-free survival (DFS), evidence supporting its overall survival (OS) benefit is limited. This manuscript critically evaluates the role of AC following CRLM resection, with a focus on patient-specific factors influencing treatment outcomes across distinct clinical scenarios. The lack of stratification by molecular biomarkers in prior trials highlights a critical gap in current evidence. Future research should integrate biomarker-driven approaches, leverage circulating tumor DNA (ctDNA) for treatment stratification, and explore novel therapies, including immunotherapies and targeted agents, in both perioperative and adjuvant settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.